semaglutide

39 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference redu

Section: CardiologyNov 11, 2025

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad

semaglutide

Latest news

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

The Rise of Ozempic and Wegovy: Revolutionizing Weight Loss, But At What Cost?

Ozempic and the Weight Loss Revolution: Miracle Drug or Medical Hype?

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution